LON:CLIN Clinigen Group (CLIN) Share Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range 925▼ 92552-Week Range N/AVolume539,375 shsAverage Volume1.83 million shsMarket Capitalization£1.23 billionP/E Ratio64.69Dividend Yield0.82%Price TargetN/A Stock AnalysisStock Analysis Get Clinigen Group alerts: Email Address Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Clinigen Group Stock (LON:CLIN)Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.Read More Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade CLIN Stock News HeadlinesSeptember 6 at 3:28 AM | seekingalpha.comIovance Therapeutics: Historic Product, Tough Commercial OutlookApril 17, 2024 | finance.yahoo.comCompounding Pharmacy Market Size to Increase USD 29.85 Billion by 2033September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… March 13, 2024 | bloomberg.comElliott Alumnus De La Riviere Joins Tech Entrepreneur’s FundFebruary 18, 2024 | finanznachrichten.deReal World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets.September 12, 2023 | technews.tmcnet.comClinigen launches NaviGATE: an educational programme for rare disease patients and organisationsSeptember 8, 2023 | msn.comSMALL CAP MOVERS: Will Ergomed and Instem end up on the Nasdaq?August 10, 2023 | benzinga.comClinigen divests global rights to four cancer support therapies to CNX TherapeuticsSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… May 3, 2023 | marketwatch.comOral Mucositis Market Emerging Trends till 2031April 27, 2023 | marketwatch.comCompounding Pharmacies Market Size, Trends, Growth Status, Share, Research, and Forecast 2023 to 2031April 3, 2023 | markets.businessinsider.comSuccessful transaction: Adragos Pharma has officially taken over Clinigen's development unit, Lamda Laboratories near Athens, GreeceMarch 30, 2023 | marketwatch.comReal World Evidence Solutions Market 2023 Size and Forecast to 2031March 30, 2023 | marketwatch.com2023-2030 Jet Lag Treatment Market Size with Manufactures (Teva, Mylan, Nature’s Bounty)March 30, 2023 | markets.businessinsider.comEQS-News: PAION AG reports on fiscal year 2022March 28, 2023 | marketwatch.comOral Mucositis Drugs Market Growth and Forecast till 2030March 27, 2023 | marketwatch.comReal World Evidence Solutions Market Premium Research Report Forecast 2023 To 2029March 25, 2023 | marketwatch.comOral Mucositis Market Top Players and Forecast till 2031See More Headlines Receive CLIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/17/2020Today9/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Delivery Sub-IndustryTrading Current SymbolLON:CLIN CUSIPN/A CIKN/A Webwww.clinigengroup.com Phone+44-1283-495010FaxN/AEmployees1,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio64.69 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio90.77 Current Ratio1.89 Quick Ratio1.48 Sales & Book Value Annual Sales£565.60 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.48 Book ValueGBX 341.90 per share Price / BookN/AMiscellaneous Outstanding Shares133,367,000Free FloatN/AMarket Cap£1.23 billion OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Shaun Edward Chilton (Age 54)CEO & Exec. Director Comp: $662kRichard PalingInterim Chief Financial Officer & Group Financial ControllerMr. Sam HerbertChief Operating OfficerRob FoxVP of Investor Relations & Corp. Devel.Ms. Amanda MillerGen. Counsel & Company Sec.Mr. David BryantDirector of Corp. Devel.Jessica ArcherGlobal HR DirectorMr. Mark CorbettManaging Director of Global Access DivisionMr. Johannes Willemse (Age 54)Chief Commercial Officer Mr. Ivo Timmermans M.D. (Age 62)MBA, Chief Medial Officer More ExecutivesKey CompetitorsLand Securities GroupLON:LANDSafestoreLON:SAFESecure Income REITLON:SIREVRAZLON:EVRBMO Global Smaller CompaniesLON:BGSCView All Competitors CLIN Stock Analysis - Frequently Asked Questions How were Clinigen Group's earnings last quarter? Clinigen Group plc (LON:CLIN) announced its quarterly earnings results on Thursday, September, 17th. The company reported $65.60 EPS for the quarter, beating the consensus estimate of $63.50 by $2.10. How do I buy shares of Clinigen Group? Shares of CLIN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Clinigen Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Applications (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC) and NII (NIHD). This page (LON:CLIN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinigen Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinigen Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.